Mario Talajic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1662270/publications.pdf

Version: 2024-02-01

236612 214527 3,266 47 25 47 citations h-index g-index papers 48 48 48 4197 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Social Support, Depression, and Mortality During the First Year After Myocardial Infarction. Circulation, 2000, 101, 1919-1924.	1.6	542
2	New-Onset Atrial Fibrillation. Circulation, 2001, 103, 2365-2370.	1.6	344
3	Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. European Heart Journal, 2014, 35, 3346-3355.	1.0	329
4	Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial. Lancet, The, 2015, 386, 672-679.	6.3	188
5	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nature Genetics, 2021, 53, 128-134.	9.4	155
6	Pulmonary vein isolation using "contact force―ablation: The effect on dormant conduction and long-term freedom from recurrent atrial fibrillation—A prospective study. Heart Rhythm, 2014, 11, 1919-1924.	0.3	144
7	Transvenous Catheter Ice Mapping and Cryoablation of the Atrioventricular Node in Dogs. PACE - Pacing and Clinical Electrophysiology, 1999, 22, 1488-1498.	0.5	132
8	Fludrocortisone for the Prevention ofÂVasovagal Syncope. Journal of the American College of Cardiology, 2016, 68, 1-9.	1.2	116
9	Clinical Experience With a Novel Electromyographic Approach to Preventing Phrenic Nerve Injury During Cryoballoon Ablation in Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 605-611.	2.1	93
10	Feasibility of cardiac cryoablation using a transvenous steerable electrode catheter. Journal of Interventional Cardiac Electrophysiology, 1998, 2, 285-292.	0.6	88
11	The Treatment of Atrial Fibrillation. Drugs, 1994, 48, 345-371.	4.9	83
12	Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008509.	2.1	82
13	Fish Oil for the Reduction of Atrial Fibrillation Recurrence, Inflammation,Âand Oxidative Stress. Journal of the American College of Cardiology, 2014, 64, 1441-1448.	1.2	76
14	Genetic Testing in the Evaluation of Unexplained Cardiac Arrest. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	76
15	Outcome of Apparently Unexplained Cardiac Arrest. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e003619.	2.1	56
16	Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. Circulation, 2022, 145, 1693-1704.	1.6	54
17	Recent Advances in Understanding the Pharmacology of Amiodarone. Drugs, 1988, 36, 121-131.	4.9	43
18	Amiodarone: Pharmacology, Clinical Actions, and Relationships Between Them. Journal of Cardiovascular Electrophysiology, 1992, 3, 266-280.	0.8	38

#	Article	IF	CITATIONS
19	Importance of genetic testing in unexplained cardiac arrest. European Heart Journal, 2022, 43, 3071-3081.	1.0	36
20	A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. European Heart Journal, 2022, 43, e1-e9.	1.0	35
21	Comparison of Ajmaline and Procainamide Provocation Tests in the Diagnosis of Brugada Syndrome. JACC: Clinical Electrophysiology, 2019, 5, 504-512.	1.3	32
22	Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design. Canadian Journal of Cardiology, 2019, 35, 1069-1077.	0.8	27
23	Atrioventricular Interval Optimization and Exercise Tolerance. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 1534-1540.	0.5	26
24	Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion. American Heart Journal, 2014, 167, 646-652.	1.2	25
25	Infections Associated with Resterilized Pacemakers and Defibrillators. New England Journal of Medicine, 2020, 382, 1823-1831.	13.9	25
26	Is There a Future for Antiarrhythmic Drug Therapy?. Drugs, 1998, 56, 767-781.	4.9	22
27	Blood Pressure and Atrial Fibrillation: A Combined AFâ€CHF and AFFIRM Analysis. Journal of Cardiovascular Electrophysiology, 2015, 26, 509-514.	0.8	22
28	Predictors of Ventricular Arrhythmias and Sudden Death in a Québec Cohort With Brugada Syndrome. Canadian Journal of Cardiology, 2016, 32, 1355.e1-1355.e7.	0.8	19
29	Characterization of a Human Induced Pluripotent Stem Cell–Derived Cardiomyocyte Model for the Study of Variant Pathogenicity. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	17
30	Reducing Radiation Exposure During CRT Implant Procedures: Singleâ€Center Experience With Lowâ€Dose Fluoroscopy Settings and a Sensorâ€Based Navigation System (MediGuide). Journal of Cardiovascular Electrophysiology, 2016, 27, 1337-1343.	0.8	16
31	The Hearts in Rhythm Organization: A Canadian National Cardiogenetics Network. CJC Open, 2020, 2, 652-662.	0.7	14
32	One-to-Two Atrioventricular Conduction Causing Nonreentrant Tachycardia: Successful Treatment with Radiofrequency Ablation. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 1152-1154.	0.5	13
33	Reducing radiation exposure during procedures performed in the electrophysiology laboratory. Journal of Cardiovascular Electrophysiology, 2018, 29, 308-315.	0.8	13
34	Impact of Cardiac Resynchronization Therapy on Hospitalizations in the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial. Circulation, 2014, 129, 2021-2030.	1.6	10
35	Variant Reinterpretation in Survivors of Cardiac Arrest With Preserved Ejection Fraction (the Cardiac) Tj ETQq1 Laboratories. Circulation Genomic and Precision Medicine, 2021, 14, e003235.	1 0.78431. 1.6	4 rgBT /Overlo
36	Novel Gain-of-Function Variant in <i>CACNA1C</i> Associated With Timothy Syndrome, Multiple Accessory Pathways, and Noncompaction Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, e003123.	1.6	9

#	Article	IF	CITATIONS
37	Cycle Length Alternation During Supraventricular Tachycardia: Occurrence and Mechanism in a Canine Model of AV Reentrant Tachycardia. PACE - Pacing and Clinical Electrophysiology, 1990, 13, 314-325.	0.5	8
38	Pillbox Use and INR Stability in a Prospective Cohort of New Warfarin Users. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 676-684.	0.5	8
39	Risk of arrhythmic events in drug-induced Brugada syndrome. Heart Rhythm, 2017, 14, 1434-1435.	0.3	6
40	Early Repolarization Pattern Inheritance in the Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER). JACC: Clinical Electrophysiology, 2018, 4, 1473-1479.	1.3	6
41	Missense variants in the spectrin repeat domain of DSP are associated with arrhythmogenic cardiomyopathy: A family report and systematic review. American Journal of Medical Genetics, Part A, 2020, 182, 2359-2368.	0.7	6
42	Risk stratification for ventricular arrhythmias and sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy: an update. Expert Review of Cardiovascular Therapy, 2019, 17, 645-651.	0.6	5
43	Sinus Node Dysfunction and Sudden Cardiac Death Following Treatment with Encainide. PACE - Pacing and Clinical Electrophysiology, 1989, 12, 1607-1612.	0.5	4
44	Return of Results Policies for Genomic Research: Current Practices and the Hearts in Rhythm Organization (HiRO) Approach. Canadian Journal of Cardiology, 2022, 38, 526-535.	0.8	3
45	Effect Of Catheter Ablation On Quality Of Life In Atrial Fibrillation. Journal of Atrial Fibrillation, 2014, 6, 1063.	0.5	2
46	Low Energy Direct Current Ablation in Patients with the Wolff-Parkinson-White Syndrome: Clinical Outcome According to Accessory Pathway Location. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 1951-1955.	0.5	1
47	A Look Into the Future of Cardiology: Perspectives From the Montreal Heart Institute. Canadian Journal of Cardiology, 2014, 30, S399-S400.	0.8	o